These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 32653650)

  • 21. [COVID-19: a cardiological point-of-view].
    Weckbach LT; Kellnar A; Stremmel C; Stark K; Kääb S
    Dtsch Med Wochenschr; 2020 Jul; 145(15):1063-1067. PubMed ID: 32731280
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recommendations for use of a hydroxychloroquine loading dose in patients with COVID-19.
    Kara E; Demirkan K; Unal S
    Int J Antimicrob Agents; 2020 Sep; 56(3):106123. PubMed ID: 32738307
    [No Abstract]   [Full Text] [Related]  

  • 23. Novel therapeutic targets for SARS-CoV-2-induced acute lung injury: Targeting a potential IL-1β/neutrophil extracellular traps feedback loop.
    Yaqinuddin A; Kashir J
    Med Hypotheses; 2020 Oct; 143():109906. PubMed ID: 32505910
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Of chloroquine and COVID-19.
    Touret F; de Lamballerie X
    Antiviral Res; 2020 May; 177():104762. PubMed ID: 32147496
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of Anluohuaxian in the treatment of patients with severe Coronavirus disease 2019- a multicenter, open label, randomized controlled study: a structured summary of a study protocol for a randomised controlled trial.
    Zhang C; Li J; Wu Z; Wang H; Que C; Zhao H; Wang G
    Trials; 2020 Jun; 21(1):495. PubMed ID: 32513299
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Have we found the panacea to COVID-19 with remdesivir, an old but newly packaged drug?
    Thalha AMM; Lee YY; Besari A; Omar SFS
    J R Coll Physicians Edinb; 2020 Jun; 50(2):159-161. PubMed ID: 32568289
    [No Abstract]   [Full Text] [Related]  

  • 27. COVID-19 coagulopathy: an evolving story.
    The Lancet Haematology
    Lancet Haematol; 2020 Jun; 7(6):e425. PubMed ID: 32470428
    [No Abstract]   [Full Text] [Related]  

  • 28. Potential drugs for the treatment of the novel coronavirus pneumonia (COVID-19) in China.
    Pan X; Dong L; Yang L; Chen D; Peng C
    Virus Res; 2020 Sep; 286():198057. PubMed ID: 32531236
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-SARS-CoV-2 Potential of Artemisinins In Vitro.
    Cao R; Hu H; Li Y; Wang X; Xu M; Liu J; Zhang H; Yan Y; Zhao L; Li W; Zhang T; Xiao D; Guo X; Li Y; Yang J; Hu Z; Wang M; Zhong W
    ACS Infect Dis; 2020 Sep; 6(9):2524-2531. PubMed ID: 32786284
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Considering mutational meltdown as a potential SARS-CoV-2 treatment strategy.
    Jensen JD; Lynch M
    Heredity (Edinb); 2020 May; 124(5):619-620. PubMed ID: 32251365
    [No Abstract]   [Full Text] [Related]  

  • 31. Severe Acute Lung Injury Related to COVID-19 Infection: A Review and the Possible Role for Escin.
    Gallelli L; Zhang L; Wang T; Fu F
    J Clin Pharmacol; 2020 Jul; 60(7):815-825. PubMed ID: 32441805
    [TBL] [Abstract][Full Text] [Related]  

  • 32. SARS-CoV-2 and cardiovascular complications: From molecular mechanisms to pharmaceutical management.
    Wu L; O'Kane AM; Peng H; Bi Y; Motriuk-Smith D; Ren J
    Biochem Pharmacol; 2020 Aug; 178():114114. PubMed ID: 32579957
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chloroquine and hydroxychloroquine in covid-19.
    Ferner RE; Aronson JK
    BMJ; 2020 Apr; 369():m1432. PubMed ID: 32269046
    [No Abstract]   [Full Text] [Related]  

  • 34. Use of drugs with potential cardiac effect in the setting of SARS-CoV-2 infection.
    Sacher F; Fauchier L; Boveda S; de Chillou C; Defaye P; Deharo JC; Gandjbakhch E; Probst V; Cohen A; Leclercq C;
    Arch Cardiovasc Dis; 2020 May; 113(5):293-296. PubMed ID: 32354666
    [No Abstract]   [Full Text] [Related]  

  • 35. Arguments in favour of remdesivir for treating SARS-CoV-2 infections.
    Ko WC; Rolain JM; Lee NY; Chen PL; Huang CT; Lee PI; Hsueh PR
    Int J Antimicrob Agents; 2020 Apr; 55(4):105933. PubMed ID: 32147516
    [No Abstract]   [Full Text] [Related]  

  • 36. Microbicidal actives with virucidal efficacy against SARS-CoV-2.
    Ijaz MK; Whitehead K; Srinivasan V; McKinney J; Rubino JR; Ripley M; Jones C; Nims RW; Charlesworth B
    Am J Infect Control; 2020 Aug; 48(8):972-973. PubMed ID: 32461067
    [No Abstract]   [Full Text] [Related]  

  • 37. Is SARS-CoV-2 associated with liver dysfunction in COVID-19 patients?
    Ali N
    Clin Res Hepatol Gastroenterol; 2020 Sep; 44(4):e84-e86. PubMed ID: 32471656
    [No Abstract]   [Full Text] [Related]  

  • 38. Famotidine Against SARS-CoV2: A Hope or Hype?
    Ghosh R; Chatterjee S; Dubey S; Lavie CJ
    Mayo Clin Proc; 2020 Aug; 95(8):1797-1799. PubMed ID: 32753153
    [No Abstract]   [Full Text] [Related]  

  • 39. Propolis and its potential against SARS-CoV-2 infection mechanisms and COVID-19 disease: Running title: Propolis against SARS-CoV-2 infection and COVID-19.
    Berretta AA; Silveira MAD; Cóndor Capcha JM; De Jong D
    Biomed Pharmacother; 2020 Nov; 131():110622. PubMed ID: 32890967
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prescribing COVID-19 treatments: what we should never forget.
    Tunesi S; Bourgarit A
    J Infect; 2020 Aug; 81(2):e85. PubMed ID: 32405110
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.